Name in SEC filings: ACADIA PHARMACEUTICALS INC
| Program | Event | Stage | Stated timing | Filing |
|---|---|---|---|---|
| remlifanserin | /data readout | Phase 2 | August to October 2026 | EX-99.1 · |
| remlifanserin | Topline/data readout | Phase 2 | November 16-19, 2026 | 8-K · |
| trofinetide | Topline/data readout | Stage not stated | September to November 2026 | EX-99.1 · |
Source: ORION, orionbiotechai.com/company/ACAD, data as of Oct 18, 2026
https://www.orionbiotechai.com/company/ACAD
remlifanserin · Topline/data readout · November 16-19, 2026
SEC sources last checked .
○ Quote matched to filing (not yet reviewed by founder) · ✓ Checked by founder.
Topline/data readoutAugust to October 2026
Stage: Phase 2SEC filing · “Phase 2”
Public float: $2,300,000,000 · as of · SEC filing
Phase 2 topline results readout from the remlifanserin Alzheimer’s disease psychosis study remains on track for August to October 2026
EX-99.1 · Filed · Last checked
Resolution filing: · SEC filing
Alert me · Calendar: same stage and window-end month (2026-10)
Topline/data readoutNovember 16-19, 2026
Stage: Phase 2SEC filing · “Phase 2”
Public float: $2,300,000,000 · as of · SEC filing
The Company plans to present detailed safety and efficacy results from the RADIANT Phase 2 study in an oral presentation at the upcoming Clinical Trials on Alzheimer’s Disease (CTAD) conference, taking place November 16-19, 2026 in Boston.
8-K · Filed · Last checked
Alert me · Calendar: same stage and window-end month (2026-11)
Topline/data readoutSeptember to November 2026
Stage: Not stated
Public float: $2,300,000,000 · as of · SEC filing
trofinetide clinical trial in Japan, with topline results now anticipated in the September to November 2026
EX-99.1 · Filed · Last checked
Alert me · Calendar: same stage and window-end month (2026-11)
Company periods and sentences are quoted as written. A matching disclosure uses the SEC filing date for the same program and event type. As of .
| Program / event | Stated period and SEC wording | Disclosure in stated period |
|---|---|---|
| remlifanserinClinical results | November 16-19, 2026“The Company plans to present detailed safety and efficacy results from the RADIANT Phase 2 study in an oral presentation at the upcoming Clinical Trials on Alzheimer’s Disease (CTAD) conference, taking place November 16-19, 2026 in Boston.” Filed · 8-K | Period not started The stated period has not started yet, so there is nothing to compare. |
| remlifanserinClinical results | August to October 2026“Phase 2 topline results readout from the remlifanserin Alzheimer’s disease psychosis study remains on track for August to October 2026” Filed · EX-99.1 | Disclosure present SEC filing date within the stated period Filed · EX-99.1 “On September 24, 2026, the Company announced Phase 3 enabling topline results from the Phase 2 portion of the ongoing RADIANT clinical trial program evaluating remlifanserin for the treatment of hallucinations and delusions associated with ADP” |
| trofinetideClinical results | September to November 2026“trofinetide clinical trial in Japan, with topline results now anticipated in the September to November 2026” Filed · EX-99.1 | Still within period As of Oct 19, 2026 |
| remlifanserinClinical results | August to October 2026“Phase 2 top-line results readout from the remlifanserin Alzheimer’s disease psychosis study remains on track for August to October 2026” Filed · EX-99.1 | Disclosure present SEC filing date within the stated period Filed · EX-99.1 “On September 24, 2026, the Company announced Phase 3 enabling topline results from the Phase 2 portion of the ongoing RADIANT clinical trial program evaluating remlifanserin for the treatment of hallucinations and delusions associated with ADP” |
“Not compared” means ORION has not matched this wording against a complete set of SEC filings for its period. It says nothing either way about whether a matching filing exists. Wording without exact dates is not given calendar dates.
Historical summaries and source dates are retained separately from the SEC timing quotes above. Earlier publications were collected retrospectively.
Historical catalog checked .
No historical announcement trail is retained for this company in this catalog.
Original ClinicalTrials.gov record · Open the selected study
These are selected linked records and dated source metadata, not a live registry recheck or the company’s full pipeline. Company announcements and the selected registry study are separate evidence sets. No stage or event timing is borrowed between them.
Coverage and identity checksSuggest an SEC timing statement to add for ACAD. You can include the original filing link in your note. The founder reads each request by hand.
Or email ORION.
See ACAD in the calendar · Review labels and methodology